Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
NCT03454919Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of palbociclib in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
palbociclib
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT03454919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454919.